Regen BioPharma Reports Stable Revenue but Increased Operating Losses and Significant Net Income Turnaround

Regen BioPharma, Inc. reported its financial results for the quarter and six months ended March 31, 2026, revealing a net revenue of $59,065 for the quarter, consistent with the same period in 2025. For the six-month period, net revenue also remained stable at $118,129, reflecting no significant change year-over-year. The company’s revenue sources included $31,640 from standard operations and $27,425 from related party transactions, both figures unchanged from the previous year. Despite stable revenue, the company experienced a substantial increase in operating expenses, which totaled $212,774 for the quarter, up from $172,414 in the prior year, primarily driven by higher consulting and professional fees.

The company's operating loss for the quarter was $153,709, compared to a loss of $113,349 in the same quarter of 2025. This increase in loss was attributed to rising expenses across all categories except for rent, which was eliminated in the current period. Notably, Regen BioPharma reported a significant turnaround in net income, achieving $991,927 for the quarter, a stark contrast to a net loss of $19,354 in the previous year. This improvement was largely due to a substantial increase in derivative income, which reached $1,181,680, compared to $128,963 in the prior year.

For the six months ended March 31, 2026, the company recorded a net income of $24,074, a significant recovery from a net loss of $534,739 in the same period of 2025. The increase in net income was similarly driven by derivative income, which totaled $800,854 for the six-month period, compared to a loss of $287,053 in the previous year. However, total operating expenses surged to $823,462, up from $292,857, primarily due to increased consulting and administrative costs, as well as research and development expenses.

Regen BioPharma's operational metrics indicate a challenging environment, with a working capital deficit of approximately $5.3 million as of March 31, 2026. The company reported cash reserves of only $271, raising concerns about its liquidity and ability to fund ongoing operations. Management has indicated that it intends to secure additional funding through equity or debt offerings to support its business plans, although there is no guarantee of success in these endeavors. The company has also acknowledged substantial doubt regarding its ability to continue as a going concern without additional financing.

Looking ahead, Regen BioPharma is focused on advancing its regenerative medical applications, which are currently in the early stages of development. The company is actively pursuing licensing agreements and collaborations to enhance its product pipeline. However, it remains contingent on obtaining FDA approvals for its products, and the management has cautioned that there are no assurances that any of its products will receive such approvals. The company’s future financial performance will depend significantly on its ability to secure funding and successfully navigate the regulatory landscape.